Concepedia

Richard L. Dunbar

RL

Statistics

Publications

29

Citations

2.6K

H-Index

21

Active since

1994

Affiliations

University of Pennsylvania(Current)

Translational Therapeutics (United States)

Merck & Co., Inc., Rahway, NJ, USA (United States)

University of California, Los Angeles

Pennsylvania Hospital

Richard L. Dunbar is an author at University of Pennsylvania specializing in pharmacology, lipid-lowering therapy, and life sciences.

ORCID

Publications per year

1994–2025

29

Publications

29

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Frederick E. Dewey, Viktoria Gusarova, Richard L. Dunbar et al. · New England Journal of Medicine · 2017 · 875 citations · Full text

, , +15

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients

LeAnne T. Bloedon, Richard L. Dunbar, Danielle Duffy et al. · Journal of Lipid Research · 2008 · 290 citations · Full text

, , +17

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

Zahid Ahmad, Poulabi Banerjee, Sara Hamon et al. · Circulation · 2019 · 245 citations · Full text

, , +17

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Andrés Digenio, Richard L. Dunbar, Veronica Alexander et al. · Diabetes Care · 2016 · 168 citations

, , +17

Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

Brett Lauring, Andrew K.P. Taggart, James R. Tata et al. · Science Translational Medicine · 2012 · 127 citations

, , +8

1–5 of 29